Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer
通路活性分析可以预测HR+ HER2-绝经后早期乳腺癌新辅助内分泌治疗的反应
期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-026-02245-4
de Gruil, N; de Groot, A F; Wesseling-Rozendaal, Y; Keizer, D; Koekenbier, C S; Vermeer, S; Cohen, D; Heijns, J B; Mandigers, C M P W; van de Wouw, A J; Cloos-van Balen, M; Ropela, J A; Oosterkamp, H M; van Bekkum, M L; Houtsma, D; Biezen, E den; Liefers, G J; Linn, S C; Kroep, J R